




DISHMAN CARBOGEN AMCIS LIMITED

CIN : U74900GJ2007PLC051338 Email ID : dishman@dishmangroup.com Web : www.dishmangroup.com
 Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009 Phone No : 079-26443053 Fax No : 079-26420198
 Part I : Statement of Unaudited Standalone / Consolidated Results for the Quarter and Nine Months Ended 31-12-2017

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	STANDALONE					
		For The Quarter ended 31-12-2017	For The Preceding Quarter ended 30-09-2017	For The Corresponding Quarter ended 31-12-2016	For The Nine Months ended 31-12-2017	For The Corresponding Nine Months ended 31-12-2016	For The Year ended 31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income From Operations						
	a) Net sales/income from operations	76.61	123.58	97.56	293.88	295.76	408.96
	b) Other Operating Income	18.45	5.79	8.56	24.66	27.69	42.53
	Total Income from operations (net)	95.06	129.37	106.12	318.54	323.45	451.49
2	Other Income	20.89	24.46	1.97	48.91	33.25	71.25
3	Total Income	115.95	153.83	108.09	367.45	356.70	522.74
4	Expenses						
	a) Cost of materials consumed	31.35	44.67	32.32	111.68	102.77	140.40
	b) Purchase of stock-in-trade	-	2.25	8.61	4.69	8.67	13.14
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(11.62)	(3.12)	(9.26)	(25.20)	(17.88)	(10.48)
	d) Employee benefits expense	16.81	12.40	17.63	42.04	51.43	66.76
	e) Finance costs	8.25	9.42	8.73	25.02	35.94	39.17
	f) Depreciation and amortisation expense	35.92	34.02	34.09	104.13	101.76	135.85
	g) Other Expenditure	16.02	19.87	21.43	64.71	65.53	93.99
	Total expenses	96.73	119.51	113.55	327.07	348.22	478.83
5	Profit / (Loss) before share of profit from associate & joint ventures ,exceptional items and Tax (3-4)	19.22	34.32	(5.46)	40.38	8.48	43.91
6	Share of Profit from associates and Joint Ventures	-	-	-	-	-	-
	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	19.22	34.32	(5.46)	40.38	8.48	43.91
7	Exceptional Items	-	-	-	-	-	-
8	Profit/(Loss) before tax (7-8)	19.22	34.32	(5.46)	40.38	8.48	43.91
9	Tax expense	7.48	11.94	(1.93)	14.74	4.16	19.67
	- Current Tax	2.59	4.05	1.24	6.65	3.93	9.58
	- Deferred tax	4.89	7.89	(3.17)	8.09	0.23	10.09
10	Net Profit/(Loss) after tax (9-10)	11.74	22.38	(3.53)	25.64	4.32	24.24
11	Other Comprehensive Income (Net of Tax)						
	(A) Other Comprehensive Income / (expenses) not to be reclassified to profit or loss-						
	(i) Re measurement gains/ (Losses) on defined benefit plans	(0.15)	(0.14)	(0.15)	(0.43)	(0.46)	(0.57)
	(ii) Income Tax effect	0.05	0.05	0.05	0.15	0.16	0.20
	(b) (i) Changes in fair value of FVTOCI equity instruments	(0.20)	(0.22)	0.79	(0.63)	0.51	(0.84)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.08	0.07	(0.61)	0.22	(0.53)	1.34
	(B) Other Comprehensive Income / (expenses) to be reclassified to profit or loss-						
	(a) (i) Movement in Foreign currency translation reserve	-	-	-	-	-	-
	(b) (i) foreign exchange fluctuation in respect of cash flow hedge	17.20	(12.92)	-	4.28	-	-
	(ii) Income tax relating to above	(0.01)	(1.47)	-	(1.48)	-	-
12	Total Comprehensive Income for the year (11+12) (Comprising Profit/ (Loss) and Other Comprehensive Income for the period)	28.71	7.75	(3.45)	27.75	4.00	24.37
13	Earning per equity share (face value of Rs. 2/-) (Refer Note No. 6)						
	a) Basic (not annualised for the quarter)	0.73	1.39	(0.22)	1.59	0.27	1.50
	b) Diluted (not annualised for the quarter)	0.73	1.39	(0.22)	1.59	0.27	1.50






DISHMAN CARBOGEN AMCIS LIMITED

CIN : U74900GJ2007PLC051338 Email ID : dishman@dishmangroup.com Web : www.dishmangroup.com
 Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009 Phone No : 079-26443053 Fax No : 079-26420198
 Part I : Statement of Unaudited Standalone / Consolidated Results for the Quarter and Nine Months ended 31-12-2017

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	CONSOLIDATED					
		For The Quarter ended 31-12-2017	For The Preceding Quarter ended 30-09-2017	For The Corresponding Quarter ended 31-12-2016	For The Nine Months ended 31-12-2017	For The Corresponding Nine Months ended 31-12-2016	For The Year ended 31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income From Operations						
	a) Net sales/income from operations	430.91	430.79	356.47	1,200.16	1,146.76	1,633.86
	b) Other Operating Income	28.91	13.05	5.60	43.14	32.71	79.83
	Total Income from operations (net)	459.82	443.84	362.07	1,243.30	1,179.47	1,713.69
2	Other Income	14.62	9.01	15.53	30.19	22.31	26.13
3	Total Income	474.44	452.85	377.60	1,273.49	1,201.78	1,739.82
4	Expenses						
	a) Cost of materials consumed	125.89	67.50	139.17	274.08	243.80	317.43
	b) Purchase of stock-in-trade	-	2.25	-	4.68	0.06	13.14
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.47)	9.70	(74.29)	(48.46)	(32.94)	(0.28)
	d) Employee benefits expense	158.44	151.84	130.88	453.68	418.90	596.02
	e) Finance costs	12.80	13.37	13.39	37.55	38.87	49.01
	f) Depreciation and amortisation expense	54.96	54.57	51.36	160.94	156.51	213.50
	g) Other Expenditure	76.76	79.56	67.05	235.11	243.00	334.03
	Total expenses	406.38	378.79	327.56	1,117.58	1,068.20	1,522.85
5	Profit / (Loss) before share of profit from associate & joint ventures, exceptional items and Tax (3-4)	68.06	74.06	50.04	155.91	133.58	216.97
6	Share of Profit from associates and Joint Ventures	-	-	0.37	-	0.37	0.89
	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	68.06	74.06	49.67	155.91	133.21	216.08
7	Exceptional Items	-	-	-	-	-	-
9	Profit/(Loss) before tax (7-8)	68.06	74.06	49.67	155.91	133.21	216.08
10	Tax expense	26.06	25.67	17.19	52.50	38.08	70.65
	- Current Tax	21.54	12.72	15.78	39.72	36.30	56.40
	- Deferred tax	4.52	12.95	1.41	12.78	1.78	15.25
11	Net Profit/(Loss) after tax (9-10)	42.00	48.39	32.48	103.41	95.13	145.43
12	Other Comprehensive Income (Net of Tax)						
	(A) Other Comprehensive Income / (expenses) not to be reclassified to profit or loss-						
	(i) Re measurement gains/ (Losses) on defined benefit plans	(0.15)	(0.14)	(0.15)	(0.43)	(0.46)	14.56
	(ii) Income Tax effect	0.05	0.05	0.05	0.15	0.16	0.20
	(b) (i) Changes in fair value of FVTOCI equity instruments	(0.20)	(0.22)	0.79	(0.63)	0.51	(0.84)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.08	0.07	(0.61)	0.22	(0.53)	1.34
	(B) Other Comprehensive Income / (expenses) to be reclassified to profit or loss-						
	(a) (i) Movement in Foreign currency translation reserve	127.00	(16.43)	(75.52)	123.89	(117.38)	(214.02)
	(b) (i) foreign exchange fluctuation in respect of cash flow hedge	17.20	(12.92)	-	4.28	-	-
	(ii) Income tax relating to above	(0.01)	(1.47)	-	(1.48)	-	-
13	Total Comprehensive Income for the year (11+12) (Comprising Profit/(Loss) and Other Comprehensive Income for the period)	185.97	17.33	(42.96)	229.40	(22.57)	(53.33)
14	Profit for the period attributable to :						
	(a) Owners of the company	42.00	48.39	32.48	103.41	95.13	145.43
	(b) Non Controlling Interest	-	-	-	-	-	-
	Profit for the period	42.00	48.39	32.48	103.41	95.13	145.43
15	Other Comprehensive Income for the period attributable to:						
	(a) Owners of the company	143.97	(31.06)	(75.44)	126.00	(117.70)	(198.76)
	(b) Non Controlling Interest	-	-	-	-	-	-
	Other Comprehensive Income	143.97	(31.06)	(75.44)	126.00	(117.70)	(198.76)
16	Total Comprehensive Income for the period attributable to:						
	(a) Owners of the company	185.97	17.33	(42.96)	229.40	(22.57)	(53.33)
	(b) Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income	185.97	17.33	(42.96)	229.40	(22.57)	(53.33)
17	Earnings per equity share (face value of Rs. 2/-) (Refer Note No. 6)						
	(a) Basic (not annualised for the quarter)	2.60	3.00	2.01	6.41	5.89	9.01
	(b) Diluted (not annualised for the quarter)	2.60	3.00	2.01	6.41	5.89	9.01




Segment wise Revenue, Result and Capital Employed							
Sr. No	PARTICULARS	For The Quarter ended 31-12-2017	For The Preceding Quarter ended 30-09-2017	For The Corresponding Quarter ended 31-12-2016	For The Nine Months ended 31-12-2017	For The Corresponding Nine Months ended 31-12-2016	For The Year ended 31-03-2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	(a) CRAMS	330.26	336.58	247.69	913.98	829.30	1,179.77
	(b) Others	100.65	94.21	108.78	286.18	317.46	454.09
	Total	430.91	430.79	356.47	1,200.16	1,146.76	1,633.86
	Less: Inter-segment Revenue	-	-	-	-	-	-
	Net Sales /Income from Operation	430.91	430.79	356.47	1,200.16	1,146.76	1,633.86
2	Segment Results (Profit/(Loss) before tax and interest from each segment)						
	(a) CRAMS*	52.19	61.58	43.90	127.39	103.38	148.97
	(b) Others*	14.05	16.84	4.00	35.88	46.76	61.30
	Total	66.24	78.42	47.90	163.27	150.14	210.27
	Less: i) Interest	12.80	13.37	13.39	37.55	38.87	49.01
	ii) Other un-allocable expenditure net off un-allocable income	(14.62)	(9.01)	(15.53)	(30.19)	(22.31)	(55.71)
	Total Profit/(Loss) Before Tax	68.06	74.06	50.04	155.91	133.58	216.97

* Includes Forex (Loss) / Gain



* For Segmental Capital Employed : Refer Note : 12

Place: Ahmedabad
Date: 24th January, 2018



For and on behalf of the Board

[Handwritten Signature]
Arpit J. Vyas
Managing Director and CFO



Notes:




1. The Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 24th January, 2018. These financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013.
2. Joint Statutory Auditors have carried out a "Limited Review" of the standalone as well as consolidated financial results of the Company for the quarter and nine months ended 31st December, 2017.
3. The Hon'ble High Court of Gujarat, vide its order dated 16th December, 2016 sanctioned the Scheme of Arrangement and Amalgamation involving merger of Dishman Pharmaceuticals and Chemicals Ltd. ("DPCL") and Dishman Care Ltd. ("DCL") with Dishman Carbogen Amcis (India) Ltd. (formerly known as Carbogen Amcis (India) Ltd.) ("DCAL" or "the Company") in terms of the provisions of Section 391 to 394 of the Companies Act, 1956 ("Scheme") with appointed date of 1st January, 2015. The Scheme has become effective upon filing of certified copy of said order of Hon'ble High Court with the Office of Registrar of Companies, Gujarat/MCA on 17th March, 2017 ("Effective Date") and accordingly has been given effect in the books of accounts in year 2016-17.
4. The amalgamation had been accounted in the previous year under the "Purchase Method" as per the then prevailing Accounting Standard 14 – Accounting for Amalgamations, as referred to in the Scheme of Amalgamation approved by the Hon'ble High Court, Gujarat, which is different from Ind AS 103 "Business Combinations". The excess of consideration payable over net assets acquired had been recorded as goodwill amounting Rs.1326.86 crores, represented by underlying intangible assets acquired on amalgamation and is being amortized over the period of 15 years from the Appointed Date.

Had the goodwill not been amortized as required under Ind AS 103, the Depreciation and Amortization expense for the quarter ended 31st December, 2017, 30th September, 2017, 31st December, 2016 and nine months ended 31st December, 2017, 31st December, 2016 and year ended March 31, 2017 would have been lower by Rs.22.11 crores, Rs.22.11 crores, Rs.22.11 crores, Rs.66.33 crores, Rs.66.33 crores and Rs.88.45 crores, respectively, and the Profit Before Tax for the corresponding periods would have been higher by an equivalent amount.

5. Pursuant to the Scheme, the Company has allotted 16,13,94,272 equity shares of Rs.2/- each as fully paid-up to the shareholders of erstwhile Dishman Pharmaceuticals and Chemicals Ltd. in the ratio of 1:1 to those shareholders whose names appear in the Register of Members/List of Beneficial owners as on the date of Record Date i.e. on 31st May, 2017.
6. Upon the Scheme becoming effective, the Share Capital of DCAL held by its holding company DPCL stand cancelled. Accordingly, EPS for the quarter ended 31st December, 2016, nine months ended 31st December, 2016 and year ended 31st March, 2017 has been calculated based on outstanding shares of DPCL.
As per Ind AS – 33 "Earnings per share", EPS is to be calculated on the basis of Net Profit after tax and amounts under Other Comprehensive Income (Net of tax) are not to be considered.
7. The standalone and consolidated figures of the Company for the quarter and nine months ended 31st December, 2016 have been prepared on the basis of published results of DPCL after giving effect of the Scheme from the beginning of the year i.e. 1st April, 2016. The auditors had carried out limited review of standalone and consolidated financial results of DPCL for the quarter and nine months ended 31st December, 2016 and have verified the Scheme adjustments made therein.

8. The previous period/year figures have been re-grouped, re-cast and re-arranged wherever considered necessary.

9. The Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website: www.dishmangroup.com as well as on the Stock Exchange's websites i.e. on www.bseindia.com, and www.nseindia.com.



10. As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Results.

11. The business segments of the Company comprise the followings:


Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Manufacturing of Bulk Drugs, Intermediates, Quats, Speciality Chemicals, Vitamin D3 analogue, Disinfectants and Traded Goods

12. As certain assets of the Company including manufacturing facilities, development facilities and financial assets and liabilities are often deployed interchangeably across segment, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the segment information.




13. Consolidated financial results comprise the results of the parent Company, Dishman Carbogen Amcis Limited and its subsidiaries viz. Dishman Europe Limited, Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd, Dishman Switzerland Limited, CARBOGEN AMCIS Holdings AG. (formerly known as Dishman Pharma Solutions AG), Switzerland; CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co. Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Carbogen Amcis Ltd., U.K. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Switzerland, Dishman Australasia Pty. Ltd., CARBOGEN AMCIS SAS, Dishman Middle East (FZE), Dishman Japan Limited and Dishman Carbogen Amcis (Singapore) Pte. Ltd.

Place: Ahmedabad
Date: 24th January, 2018

On behalf of the Board of Directors



Arpit J. Vyas
Managing Director & CFO
DIN - 01540057





Limited Review Report on the Unaudited Standalone Financial Results for the quarter ended December 31, 2017 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors

Dishman Carbogen Amcis Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Dishman Carbogen Amcis Limited** (“the Company”) for the quarter ended December 31, 2017 (“the Statement”), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” as prescribed under Section 133 of Companies Act, 2013 (“the Act”) read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016



dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.


4. We draw attention to Note 4 of the Statement detailing the accounting treatment relating to the Scheme involving merger of Dishman Pharmaceuticals and Chemicals Limited and Dishman Care Limited with Dishman Carbogen Amcis Limited, which has been accounted in the previous year under the "Purchase Method" as per the then prevailing Accounting Standard 14 - Accounting for Amalgamation (AS 14) in compliance with scheme of Amalgamation pursuant to Section 391 to 394 of Companies Act, 1956 approved by Hon'ble High Court of Gujarat. In accordance with the Scheme, the Company has recognized goodwill on amalgamation amounting to ₹ 1,326.86 Crores which is amortised over its useful life. This accounting treatment is different from that prescribed under Indian Accounting Standard (Ind AS 103) - 'Business Combinations'. Had the goodwill not been amortised as required under Ind AS 103, the Depreciation and Amortisation expense for the quarter ended December 31, 2017 would have been lower by ₹ 22.11 Crores and Profit before tax for the quarter ended December 31, 2017 would have been higher by an equivalent amount. Our opinion is not modified in respect of this matter.
5. The standalone financial results for the quarter and nine months ended December 31, 2016 have been prepared on the basis of published results of erstwhile Dishman Pharmaceuticals and Chemicals Limited after giving effect of the Scheme from the beginning of the year i.e. 1st April, 2016. We had reviewed the standalone financial results of erstwhile Dishman Pharmaceuticals and Chemicals Limited for the quarter and nine months ended 31st December, 2016 and have verified the Scheme adjustments made therein.

For V. D. Shukla & Co.
Chartered Accountants
ICAI Firm Registration No.110240W



Vimal D. Shukla
Proprietor
Membership No. 036416


Place : Ahmedabad
Date : January 24, 2018



For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048



Hemant J. Bhatt
Partner
Membership No. 036834





Limited Review Report on the Unaudited Consolidated Financial Results for the quarter ended December 31, 2017 pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015



To The Board of Directors

Dishman Carbogen Amcis Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Dishman Carbogen Amcis Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the quarter ended December 31, 2017 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Holding Company's management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Holding Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We believe that the review procedures performed by us and performed by the other auditors in terms of their report referred to in paragraph 7 below, is sufficient and appropriate to provide a basis for our reporting on the Statement.



4. Based on our review conducted as above, on consideration of the reports of the other auditors referred to in paragraph 7 below and based on the consideration of interim financial information furnished to us by the Management referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognised accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 4 of the Statement detailing the accounting treatment relating to the Scheme involving merger of Dishman Pharmaceuticals and Chemicals Limited and Dishman Care Limited with Dishman Carbogen Amcis Limited, which has been accounted in the previous year under the "Purchase Method" as per the then prevailing Accounting Standard 14 - Accounting for Amalgamation (AS 14) in compliance with Scheme of Amalgamation pursuant to Section 391 to 394 of Companies Act, 1956 approved by Hon'ble High Court of Gujarat. In accordance with the Scheme, the Company has recognized goodwill on amalgamation amounting to ₹ 1,326.86 Crores which is amortised over its useful life. This accounting treatment is different from that prescribed under Indian Accounting Standard (Ind AS 103) - 'Business Combinations'. Had the goodwill not been amortised as required under Ind AS 103, the Depreciation and Amortisation expense for the quarter ended December 31, 2017 would have been lower by ₹ 22.11 Crores and Profit before tax for the quarter ended December 31, 2017 would have been higher by an equivalent amount. Our opinion is not modified in respect of this matter.
6. The consolidated financial results for the quarter and nine months ended December 31, 2016 have been prepared on the basis of published results of erstwhile Dishman Pharmaceuticals and Chemicals Limited after giving effect of the Scheme from the beginning of the year i.e. 1st April, 2016. We had reviewed the consolidated financial results of erstwhile Dishman Pharmaceuticals and Chemicals Limited for the quarter and nine months ended 31st December, 2016 and have verified the Scheme adjustments made therein.



7. We did not review the financial results of nine (9) subsidiaries included in the Statement, whose financial results reflect total revenue of ₹ 418.80 crores and total profit after tax of ₹ 82.45 crores for the quarter ended December 31, 2017, as considered in the Statement. These financial results have been reviewed by the other auditors whose reports have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors. Our report is not modified in respect of this matter.
8. We did not review the financial results of seven (7) subsidiaries included in the Statement, whose financial results reflects total revenue of ₹ 4.56 crores and total profit after tax of ₹ 13.13 crores for the quarter ended December 31, 2017, as considered in the Statement. These financial results are not reviewed by their auditors and have been furnished to us by the Management and our reporting on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on such un-reviewed financial results. According to the information and explanations given to us by the Management, these financial results are not material to the Group. Our report is not modified in respect of this matter.

For V. D. Shukla & Co.

Chartered Accountants

ICAI Firm Registration No.110240W




Vimal D. Shukla

Proprietor

Membership No. 036416

Place: Ahmedabad

Date: January 24, 2018



For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048



Hemant J. Bhatt

Partner

Membership No. 036834

